Holy Stone Healthcare Co., Ltd. (TPEX:4194)

Market Cap	1.06B -6.1%
Revenue (ttm)	n/a
Net Income	-111.35M
EPS	-0.76
Shares Out	145.97M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,437
Open	7.28
Previous Close	7.27
Day's Range	6.93 - 7.28
52-Week Range	5.32 - 12.65
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Holy Stone Healthcare

Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcera...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4194

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error